Answers are grounded in this paper and cite their sources.
To the Editor: Strongyloides stercoralis, an intestinal nematode that parasitizes humans, has a large geographic distribution, being endemic in tropical and subtropical regions. Through the unique characteristic of this parasite to complete an autoinfection cycle, infective larvae (L3) can invade intestinal mucosa to maintain the infection for long periods of time, even enhancing it. Severe clinical forms, called hyperinfection or disseminated infection, have been described in patients with immunosuppression secondary to lymphatic malignancies, human T-cell lymphotropic virus type-1 (HTLV-1) infection, and in those using steroid therapies to treat rheumatologic diseases, chemotherapy, posttransplantation, and pemphigus.1 Despite a lower frequency than expected during the early AIDS epidemic, reports of disseminated/hyperinfection strongyloidiasis in the setting of HIV infection have been reported.1-3 This low incidence of disseminated strongyloidiasis in AIDS patients is not clearly understood because the profound host cellular immunodepression and pathogenetic characteristics of strongyloidiasis could lead to an unfavorable outcome. Viney et al4 proposed that the low number of CD4 T lymphocytes hinders the maturation of larval stages of the parasite. Corticosteroid therapy is frequently used as adjunct therapy to treat opportunistic diseases in HIV-infected patients, and it could explain many cases of disseminated strongyloidiasis in this context. We report 7 cases of severe clinical forms of strongyloidiasis in HIV/AIDS patients and discuss the involvement of corticosteroid therapy as an eventual predisposing factor for the dissemination of this helminthiasis. From January 1990 to March 2007, the records of all patients with a discharge diagnosis or postmortem findings of strongyloidiasis at our teaching hospital were retrospectively reviewed. Our hospital is a 3000-bed tertiary care institution, located in the southeast region of Brazil, and receives patients from many cities in São Paulo State and from other Brazilian regions. We evaluated 256 patients with S. stercoralis infection. One hundred thirteen were tested for HIV infection and 34 of them had it confirmed. Of these, 6 had disseminated and 1 hyperinfection strongyloidiasis (Table 1). Disseminated infection was defined by the occurrence of infection in sites that do not take part in the normal parasite cycle (duodenum, jejune, and/or lungs).1TABLE 1: Characteristics HIV/AIDS Patients With Disseminated/Hyperinfection Strongyloidiasis, Hospital Das Clínicas, São Paulo, Brazil (1990-2007)Complicated strongyloidiasis does not seem to be a major problem in the context of AIDS. Since the beginning of the AIDS epidemic, disseminated strongyloidiasis has been observed only in a small number of patients. Herein, we report only 7 cases of disseminated/hyperinfection strongyloidiasis over a period of 16 years in this tertiary hospital. Use of corticosteroids has been described as one of the most important predisposing factors for the development of disseminated strongyloidiasis in any setting.5 Besides corticosteroids' immune-depressing action mainly related to eosinophils,6 ecdysteroid-like activity exerted by this drug could be one of the possible explanations for this association.7 In our cohort, all but one patient had CD4 T-lymphocyte counts <100 cells/mm3. Three patients were taking steroids for neurotoxoplasmosis at the time of strongyloidiasis diagnosis. The patient with CD4 T lymphocytes >200 cells/mm3 was a chronic prednisone user who had Wegener disease. This observation once more highlights the importance of corticosteroid therapy in the genesis of disseminated strongyloidiasis in AIDS patients. Those who were not receiving corticosteroids had intense immune dysfunction demonstrated by a low CD4 T-lymphocyte count (54, 19, and 14 cells/mm3). Moreover, 2 of them had intestinal integrity alteration that could have contributed to dissemination of strongyloidiasis (intestinal microsporidiosis and ancylostomiasis). HTLV-1 coinfection data were not available in this series. The eventual interference of this viral infection in the clinical course of strongyloidiasis could not be determined. In this cohort, corticotherapy may have had an important role in the development of severe forms of strongyloidiasis in AIDS patients. Chronic strongyloidiasis not diagnosed in AIDS patients could result in a serious, life-threatening disease, especially when steroid therapy is used as adjuvant to treat some opportunistic infections like neurotoxoplasmosis, neurocryptococcosis, or neurotuberculosis and in the treatment of immune reconstitution inflammatory syndrome. AIDS patients in countries, where strongyloidiasis is endemic or that receive immigrants/refugees from areas where strongyloidiasis is endemic, should be carefully investigated for chronic strongyloidiasis, taking into account the difficulties of diagnosis.8 Preemptive treatment, before steroid therapy is initiated, should be considered if the best parasitological and serological methods are not available. Rinaldo F. Siciliano, MD Melissa Mascheretti, MD Yeh Li Ho, MD Ronaldo C. B. Gryschek, MD, PhD Division and Department of Infectious and Parasitic Hospital das Clinicas University of São Paulo School of Medicine São Paulo, Brazil
No takes yet. Share an insight, caveat, or question.
Siciliano et al. (2008) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: